Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation.

doi:10.3324/haematol.2016.146654

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation.

Haematologica - 1 Aug 2016

Alvarez-Larrán Alberto, Pereira Arturo, Guglielmelli Paola, Hernández-Boluda Juan Carlos, Arellano-Rodrigo Eduardo, Ferrer-Marín Francisca, Samah Alimam, Griesshammer Martin, Kerguelen Ana, Andreasson Bjorn, Burgaleta Carmen, Schwarz Jiri, García-Gutiérrez Valentín, Ayala Rosa, Barba Pere, Gómez-Casares María Teresa, Paoli Chiara, Drexler Beatrice, Zweegman Sonja, McMullin Mary F, Samuelsson Jan, Harrison Claire, Cervantes Francisco, Vannucchi Alessandro M, Besses Carlos

Abstract excerpt

The role of antiplatelet therapy as primary prophylaxis of thrombosis in low-risk essential thrombocythemia has not been studied in randomized clinical trials. We assessed the benefit/risk of low-dose aspirin in 433 patients with low-risk essential thrombocythemia (271 with a CALR mutation, 162 with a JAK2(V617F) mutation) who were on antiplatelet therapy or observation only. After a follow up of 2215...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Calreticulin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hemorrhage

Share to Incidence

Share to Janus Kinase 2

Share to Leukocyte Count

Share to Platelet Aggregation Inhibitors

Share to Thrombocythemia, Essential

Share to Thrombosis

Source

Open in PubMed Open full text

Identifiers

PMID: 27175028
DOI: 10.3324/haematol.2016.146654
PMCID: PMC4967571

Genes

CALR
JAK2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation.PMID 27175028Read ↗

The risk of thrombosis in essential thrombocythemia is associated with the type of CALR mutation: A multicentre collaborative study.Semantic proximity Read ↗

Cytoreductive treatment in patients with CALR-mutated essential thrombocythaemia: a study comparing indications and efficacy among genotypes from the Spanish Registry of Essential Thrombocythaemia.Semantic proximity Read ↗

Analysis of CALR-mutated essential thrombocythemia as a distinct disease entity compared with JAK2 V617F-mutated and triple-negative patients.Semantic proximity Read ↗

Aspirin therapy is associated with a lower risk of pregnancy loss in both JAK2- and CALR-mutated essential thrombocythemia-A Mayo Clinic study of 200 pregnancies.Semantic proximity Read ↗

Long-term follow-up of essential thrombocythemia patients treated with anagrelide: subgroup analysis according to JAK2/CALR/MPL mutational status.Semantic proximity Read ↗

Comparative thrombotic risk associated with CALR1 , CALR2 , and JAK2 V617F mutations in essential thrombocythemiaSemantic proximity Read ↗

Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis.Semantic proximity Read ↗

JAK2 V617F, MPL, and CALR mutations in essential thrombocythaemia and major thrombotic complications: a single-institute retrospective analysis.Semantic proximity Read ↗

Estimation of diagnosis and prognosis in ET by assessment of CALR and JAK2V617F mutations and laboratory findings: a meta-analysis.Semantic proximity Read ↗

JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.Semantic proximity Read ↗

Thrombotic risk correlates with mutational status in true essential thrombocythemia.Semantic proximity Read ↗

A meta-analysis comparing clinical characteristics and outcomes in CALR-mutated and JAK2V617F essential thrombocythaemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.